Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseTherapeutic drug monitoring in inflammatory bowel diseaseOptimizing the use of biological therapy in patients with inflammatory bowel diseaseObesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseEffects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseasePharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Endoscopic scoring systems for inflammatory bowel disease: pros and cons.Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Biologic concentration testing in inflammatory bowel disease.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.Biologic agents for IBD: practical insights.Use of anti-TNF drug levels to optimise patient management.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.Can We Predict the Efficacy of Anti-TNF-α Agents?Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.Optimization of biologic therapy in Crohn's disease.C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab.
P2860
Q24185835-FCDBFACC-96A4-4B6A-955F-7A6CEB634E89Q26745721-59530688-98A8-4B34-9150-7B4ECC1CA750Q26852729-D64F3F47-8AAE-4CE5-9F31-C2453AD385B7Q27025513-52CE2E1B-5EBF-4F58-852A-532EFFCC8742Q30239737-7E59D3C9-FAD5-49D2-A8FD-86068DB9088CQ33656852-14005298-FD84-4AC6-B21A-B06CBD1B83A8Q35559305-9109CECE-85D5-47E5-AEC8-77BF9A020201Q36347059-40B282CD-2A01-4162-B6CF-C93B31026B5BQ37275504-013DD93A-925E-4707-80B7-38A36ACD650FQ37523503-2BE2507A-BDEC-4059-A043-37156D84C39BQ37604498-EE3E07D1-7B65-40EB-8983-BC0D4BFBB58FQ38197726-2694D2E1-CC40-4901-8070-98A9C142F29DQ38248218-2FB1280F-4064-4F41-ADAC-4C21F71500ACQ38317338-6F3BFC98-6789-4C6E-8B04-F563D65DFE77Q38319306-8353C6DB-A342-4B63-BA6D-ED82C9CB808AQ38323592-4C8FAA85-F66E-46F6-9167-D672987D99C8Q38364461-C05FA53F-3F6C-4E52-903D-6E9960E086EBQ38568898-3A43F1FF-5792-44B0-BAAC-DF79DC0A69F0Q38608951-123F4F25-BD53-4BF6-B9D0-669E178C22E8Q38619950-6B037691-EC59-4B9D-B596-9F6A7DA8D928Q38620415-BF82BCED-2C9E-4EA2-B585-7C7496AFEC45Q38673082-27A3E815-D760-4A1C-9481-D54EE6F80F54Q38694153-C1BDFE2D-0879-4A95-9841-724B4BA897AAQ38719570-5F3680B5-1A30-4061-A01F-4D2AE00C8BA5Q38826447-81EA30E1-43CD-47C0-B53E-B88E7DA0A1B2Q38849974-86AFDB9C-3EE1-412C-B597-117539A1FA4CQ38869663-95C56A72-ABF9-4E18-9549-55B7F3803A31Q38883761-DDC36B95-5A7B-40D8-A578-28ACC3199A4DQ39030608-22D28D6A-7115-450D-8683-55F3AE622B77Q39317326-D35725C3-B86C-4AD2-9FCE-58E61DB6CAB2Q39834984-D9863060-9D7F-4B95-ADE6-F5A2A5DC2817Q40703329-5BF90A67-347B-41D3-A278-9CE1B415A9FAQ41308535-FA092B2F-D26E-4FBD-A570-B87EFFBF7484Q41482221-8C7628A6-2718-4DE0-9C37-7FB9F1528101Q41660559-9E353632-DEA7-4E31-B386-707F6F074ACEQ42373188-0734D5B0-C7BC-41E0-A5E1-DFBBC8CC60B5Q42695266-E92445FF-3FF7-499D-A8FA-50F00392062DQ46756144-F05B61CA-0192-42D7-AD3F-101027194015Q47389870-343B9A1A-9751-4AD5-B851-C117A2A01B70Q47422402-084EFC1A-90F3-47D9-B4F4-EA2A40FCA2F4
P2860
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Association between plasma con ...... patients with Crohn's disease.
@ast
Association between plasma con ...... patients with Crohn's disease.
@en
type
label
Association between plasma con ...... patients with Crohn's disease.
@ast
Association between plasma con ...... patients with Crohn's disease.
@en
prefLabel
Association between plasma con ...... patients with Crohn's disease.
@ast
Association between plasma con ...... patients with Crohn's disease.
@en
P2093
P50
P1476
Association between plasma con ...... patients with Crohn's disease.
@en
P2093
Bosny Pierre-Louis
Gerald Parker
Jean-Louis Dupas
Matthieu Allez
Olivier Dewit
Xavier Hébuterne
Yoram Bouhnik
P304
P356
10.1016/J.CGH.2013.10.025
P407
P577
2013-11-01T00:00:00Z